Genetic basis for clinical expression in multiple sclerosis

L. F. Barcellos, J. R. Oksenberg, A. J. Green, P. Bucher, J. B. Rimmler, S. Schmidt, M. E. Garcia, R. R. Lincoln, Margaret A Pericak-Vance, J. L. Haines, S. L. Hauser

Research output: Contribution to journalArticle

139 Citations (Scopus)

Abstract

Multiple sclerosis is a clinically heterogeneous demyelinating disease and an important cause of acquired neurological disability. An underlying complex genetic susceptibility plays an important role in multiple sclerosis aetiology; however, the role of genetic factors in determining clinical features of multiple sclerosis is unknown. We studied 184 stringently ascertained Caucasian multiple sclerosis families with multiple affected cases. A detailed evaluation of patient histories identified clinical variables including age of onset, initial clinical manifestations and disease severity. The concordance within families for continuous and categorical clinical variables was investigated using an intraclass correlation or Cohen's kappa coefficient, respectively. Genetic analyses included model-dependent, model-independent and association methodology. Linear and logistic regression models were used to evaluate the effect of human leucocyte antigen (HLA)-DR2 (DRB1*1501, DQB1*0602) on clinical outcome, taking account of correlation within families. Significant concordance for early clinical manifestations within families was observed for individuals with exclusive optic neuritis and/or spinal cord involvement as first and second multiple sclerosis attacks (P ≤ 10-6). Linkage (LOD = 3.80, θ = 0.20) and association (P = 0.0002) to HLA-DR were present in the dataset; however, linkage was restricted to families in which the DR2 haplotype was present in at least one nuclear member. No evidence for linkage to HLA-DR in DR2-negative families was observed. When families were stratified by concordance of early clinical manifestations, a significant DR2 association was present in all subgroups. Concordance for early manifestations of multiple sclerosis was present in this familial dataset, but was not associated with HLA-DR2. The association of DR2 in families with different clinical presentations suggests that a common basis exists for susceptibility in multiple sclerosis. However, non-HLA genes or other epigenetic factors must modulate disease expression. Locus heterogeneity at the HLA region suggests a distinct immunopathogenesis in DR2 negative patients.

Original languageEnglish
Pages (from-to)150-158
Number of pages9
JournalBrain
Volume125
Issue number1
StatePublished - Jan 31 2002
Externally publishedYes

Fingerprint

Multiple Sclerosis
HLA Antigens
Logistic Models
Optic Neuritis
Demyelinating Diseases
Genetic Predisposition to Disease
Age of Onset
Epigenomics
Haplotypes
Linear Models
Spinal Cord
Genes

Keywords

  • Autoimmunity
  • EAE
  • HLA-DR
  • Human
  • Multiple sclerosis

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Barcellos, L. F., Oksenberg, J. R., Green, A. J., Bucher, P., Rimmler, J. B., Schmidt, S., ... Hauser, S. L. (2002). Genetic basis for clinical expression in multiple sclerosis. Brain, 125(1), 150-158.

Genetic basis for clinical expression in multiple sclerosis. / Barcellos, L. F.; Oksenberg, J. R.; Green, A. J.; Bucher, P.; Rimmler, J. B.; Schmidt, S.; Garcia, M. E.; Lincoln, R. R.; Pericak-Vance, Margaret A; Haines, J. L.; Hauser, S. L.

In: Brain, Vol. 125, No. 1, 31.01.2002, p. 150-158.

Research output: Contribution to journalArticle

Barcellos, LF, Oksenberg, JR, Green, AJ, Bucher, P, Rimmler, JB, Schmidt, S, Garcia, ME, Lincoln, RR, Pericak-Vance, MA, Haines, JL & Hauser, SL 2002, 'Genetic basis for clinical expression in multiple sclerosis', Brain, vol. 125, no. 1, pp. 150-158.
Barcellos LF, Oksenberg JR, Green AJ, Bucher P, Rimmler JB, Schmidt S et al. Genetic basis for clinical expression in multiple sclerosis. Brain. 2002 Jan 31;125(1):150-158.
Barcellos, L. F. ; Oksenberg, J. R. ; Green, A. J. ; Bucher, P. ; Rimmler, J. B. ; Schmidt, S. ; Garcia, M. E. ; Lincoln, R. R. ; Pericak-Vance, Margaret A ; Haines, J. L. ; Hauser, S. L. / Genetic basis for clinical expression in multiple sclerosis. In: Brain. 2002 ; Vol. 125, No. 1. pp. 150-158.
@article{eabc09133949499e84870264da85c36a,
title = "Genetic basis for clinical expression in multiple sclerosis",
abstract = "Multiple sclerosis is a clinically heterogeneous demyelinating disease and an important cause of acquired neurological disability. An underlying complex genetic susceptibility plays an important role in multiple sclerosis aetiology; however, the role of genetic factors in determining clinical features of multiple sclerosis is unknown. We studied 184 stringently ascertained Caucasian multiple sclerosis families with multiple affected cases. A detailed evaluation of patient histories identified clinical variables including age of onset, initial clinical manifestations and disease severity. The concordance within families for continuous and categorical clinical variables was investigated using an intraclass correlation or Cohen's kappa coefficient, respectively. Genetic analyses included model-dependent, model-independent and association methodology. Linear and logistic regression models were used to evaluate the effect of human leucocyte antigen (HLA)-DR2 (DRB1*1501, DQB1*0602) on clinical outcome, taking account of correlation within families. Significant concordance for early clinical manifestations within families was observed for individuals with exclusive optic neuritis and/or spinal cord involvement as first and second multiple sclerosis attacks (P ≤ 10-6). Linkage (LOD = 3.80, θ = 0.20) and association (P = 0.0002) to HLA-DR were present in the dataset; however, linkage was restricted to families in which the DR2 haplotype was present in at least one nuclear member. No evidence for linkage to HLA-DR in DR2-negative families was observed. When families were stratified by concordance of early clinical manifestations, a significant DR2 association was present in all subgroups. Concordance for early manifestations of multiple sclerosis was present in this familial dataset, but was not associated with HLA-DR2. The association of DR2 in families with different clinical presentations suggests that a common basis exists for susceptibility in multiple sclerosis. However, non-HLA genes or other epigenetic factors must modulate disease expression. Locus heterogeneity at the HLA region suggests a distinct immunopathogenesis in DR2 negative patients.",
keywords = "Autoimmunity, EAE, HLA-DR, Human, Multiple sclerosis",
author = "Barcellos, {L. F.} and Oksenberg, {J. R.} and Green, {A. J.} and P. Bucher and Rimmler, {J. B.} and S. Schmidt and Garcia, {M. E.} and Lincoln, {R. R.} and Pericak-Vance, {Margaret A} and Haines, {J. L.} and Hauser, {S. L.}",
year = "2002",
month = "1",
day = "31",
language = "English",
volume = "125",
pages = "150--158",
journal = "Brain",
issn = "0006-8950",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Genetic basis for clinical expression in multiple sclerosis

AU - Barcellos, L. F.

AU - Oksenberg, J. R.

AU - Green, A. J.

AU - Bucher, P.

AU - Rimmler, J. B.

AU - Schmidt, S.

AU - Garcia, M. E.

AU - Lincoln, R. R.

AU - Pericak-Vance, Margaret A

AU - Haines, J. L.

AU - Hauser, S. L.

PY - 2002/1/31

Y1 - 2002/1/31

N2 - Multiple sclerosis is a clinically heterogeneous demyelinating disease and an important cause of acquired neurological disability. An underlying complex genetic susceptibility plays an important role in multiple sclerosis aetiology; however, the role of genetic factors in determining clinical features of multiple sclerosis is unknown. We studied 184 stringently ascertained Caucasian multiple sclerosis families with multiple affected cases. A detailed evaluation of patient histories identified clinical variables including age of onset, initial clinical manifestations and disease severity. The concordance within families for continuous and categorical clinical variables was investigated using an intraclass correlation or Cohen's kappa coefficient, respectively. Genetic analyses included model-dependent, model-independent and association methodology. Linear and logistic regression models were used to evaluate the effect of human leucocyte antigen (HLA)-DR2 (DRB1*1501, DQB1*0602) on clinical outcome, taking account of correlation within families. Significant concordance for early clinical manifestations within families was observed for individuals with exclusive optic neuritis and/or spinal cord involvement as first and second multiple sclerosis attacks (P ≤ 10-6). Linkage (LOD = 3.80, θ = 0.20) and association (P = 0.0002) to HLA-DR were present in the dataset; however, linkage was restricted to families in which the DR2 haplotype was present in at least one nuclear member. No evidence for linkage to HLA-DR in DR2-negative families was observed. When families were stratified by concordance of early clinical manifestations, a significant DR2 association was present in all subgroups. Concordance for early manifestations of multiple sclerosis was present in this familial dataset, but was not associated with HLA-DR2. The association of DR2 in families with different clinical presentations suggests that a common basis exists for susceptibility in multiple sclerosis. However, non-HLA genes or other epigenetic factors must modulate disease expression. Locus heterogeneity at the HLA region suggests a distinct immunopathogenesis in DR2 negative patients.

AB - Multiple sclerosis is a clinically heterogeneous demyelinating disease and an important cause of acquired neurological disability. An underlying complex genetic susceptibility plays an important role in multiple sclerosis aetiology; however, the role of genetic factors in determining clinical features of multiple sclerosis is unknown. We studied 184 stringently ascertained Caucasian multiple sclerosis families with multiple affected cases. A detailed evaluation of patient histories identified clinical variables including age of onset, initial clinical manifestations and disease severity. The concordance within families for continuous and categorical clinical variables was investigated using an intraclass correlation or Cohen's kappa coefficient, respectively. Genetic analyses included model-dependent, model-independent and association methodology. Linear and logistic regression models were used to evaluate the effect of human leucocyte antigen (HLA)-DR2 (DRB1*1501, DQB1*0602) on clinical outcome, taking account of correlation within families. Significant concordance for early clinical manifestations within families was observed for individuals with exclusive optic neuritis and/or spinal cord involvement as first and second multiple sclerosis attacks (P ≤ 10-6). Linkage (LOD = 3.80, θ = 0.20) and association (P = 0.0002) to HLA-DR were present in the dataset; however, linkage was restricted to families in which the DR2 haplotype was present in at least one nuclear member. No evidence for linkage to HLA-DR in DR2-negative families was observed. When families were stratified by concordance of early clinical manifestations, a significant DR2 association was present in all subgroups. Concordance for early manifestations of multiple sclerosis was present in this familial dataset, but was not associated with HLA-DR2. The association of DR2 in families with different clinical presentations suggests that a common basis exists for susceptibility in multiple sclerosis. However, non-HLA genes or other epigenetic factors must modulate disease expression. Locus heterogeneity at the HLA region suggests a distinct immunopathogenesis in DR2 negative patients.

KW - Autoimmunity

KW - EAE

KW - HLA-DR

KW - Human

KW - Multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=0036151386&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036151386&partnerID=8YFLogxK

M3 - Article

C2 - 11834600

AN - SCOPUS:0036151386

VL - 125

SP - 150

EP - 158

JO - Brain

JF - Brain

SN - 0006-8950

IS - 1

ER -